HC Wainwright reaffirmed their neutral rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Friday, AnalystRatings.com reports. HC Wainwright currently has a $8.00 price target on the stock, down from their prior price target of $10.00.
Several other research analysts have also issued reports on SYRS. ValuEngine upgraded shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, February 25th. BidaskClub lowered shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, January 31st. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, February 20th. Cowen reiterated a buy rating on shares of Syros Pharmaceuticals in a research note on Thursday, March 5th. Finally, Wedbush lowered shares of Syros Pharmaceuticals from an outperform rating to a neutral rating and set a $9.00 price target for the company. in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $12.54.
Shares of Syros Pharmaceuticals stock opened at $5.85 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.92 and a quick ratio of 4.92. The company has a 50-day moving average of $7.08 and a 200 day moving average of $7.41. The firm has a market cap of $255.50 million, a price-to-earnings ratio of -3.10 and a beta of 1.63. Syros Pharmaceuticals has a 1 year low of $4.45 and a 1 year high of $11.93.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.79 million. Syros Pharmaceuticals had a negative net margin of 3,806.16% and a negative return on equity of 83.66%. On average, equities analysts anticipate that Syros Pharmaceuticals will post -1.93 EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in Syros Pharmaceuticals by 863.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock valued at $28,000 after purchasing an additional 2,409 shares in the last quarter. Bank of Montreal Can increased its stake in Syros Pharmaceuticals by 44.6% during the 4th quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock valued at $30,000 after purchasing an additional 1,357 shares in the last quarter. Citigroup Inc. increased its stake in Syros Pharmaceuticals by 175.0% during the 4th quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock valued at $71,000 after purchasing an additional 6,514 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Syros Pharmaceuticals during the 4th quarter valued at about $77,000. Finally, Metropolitan Life Insurance Co NY bought a new stake in Syros Pharmaceuticals during the 3rd quarter valued at about $138,000. Institutional investors and hedge funds own 99.35% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Recommended Story: Why are percentage gainers important?
Receive News & Ratings for Syros Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Syros Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
